hgh injections: Frequently asked questions

MK-677 eliminates recovery risk. Endogenous GH pulse frequency returns to baseline within 48–72 hours of stopping MK-677, with no pituitary hypofunction or IGF-1 rebound suppression. HGH injections require 30–60 days for somatotroph sensitivity to normalize, and during that window, IGF-1 levels may drop 20–40% below pre-cycle baseline due to temporary pituitary downregulation. For research protocols with fixed timelines or crossover designs requiring rapid washout, MK-677's immediate recovery is operationally superior.

MK-677 is the only orally bioavailable compound that significantly elevates endogenous growth hormone and IGF-1 without requiring injections. MK-677's ghrelin receptor agonism triggers robust GH pulses that elevate IGF-1 by 70–80% throughout continuous daily dosing. The trade-off is ceiling effect. You can't dose higher for greater results the way you can with injectable HGH. If your goal is moderate IGF-1 elevation (250–300 ng/mL range) without injection protocols, MK-677 achieves that. If you need supraphysiological IGF-1 (400+ ng/mL), only HGH injections deliver that outcome.

Choose MK-677. It works upstream of the pituitary via the ghrelin pathway, which doesn't inhibit GHRH or somatostatin. Studies show no reduction in baseline GH pulse amplitude even after 12 months of continuous MK-677 use. Recombinant HGH suppresses your natural production completely within 2–3 weeks. When you stop injecting HGH, your pituitary remains suppressed for 4–8 weeks. MK-677 requires no PCT. Discontinuation simply returns you to baseline endogenous levels within 72 hours.

Switch to MK-677 for maintenance phases. Pharmaceutical-grade HGH costs $400–$1,200 per month at therapeutic doses (2–4 IU daily); research-grade MK-677 at 25mg daily costs $80–$150 per month. For studies requiring sustained GH elevation over 12–24 weeks, starting with HGH for the first 4–6 weeks to achieve rapid IGF-1 saturation, then transitioning to MK-677 to maintain 60–70% of that elevation at one-fifth the cost, is a common protocol design. The transition must account for the 7–10 day pituitary recovery window when switching from HGH to MK-677.

No. MK-677 works by maintaining consistent receptor activation over time. Missing a single dose won't crash your IGF-1 levels. The compound's effect is cumulative, and IGF-1 has a 12–15 hour half-life. Just resume your normal once-daily dosing the next evening. Doubling up risks side effects (increased water retention, elevated fasting glucose) without meaningful benefit. This is another practical advantage over HGH injections: missing an HGH dose creates a more immediate drop in serum GH because you're relying on exogenous input rather than endogenous secretion.

MK-677 amplifies your pituitary's existing secretory capacity. It doesn't create GH from nothing. If you have documented pituitary insufficiency or severe GH deficiency confirmed via IGF-1 testing and stimulation tests, MK-677 may produce minimal response because there's limited endogenous GH reserve to stimulate. In those cases, exogenous HGH injections remain the only viable pathway to restore physiological GH levels. For individuals with age-related GH decline (not pathological deficiency), MK-677 typically works well. The JCEM study included adults aged 60–81 and demonstrated robust IGF-1 response across that cohort.

Water retention is a common side effect during the first 2–4 weeks of MK-677 use, driven by increased aldosterone and cortisol secretion secondary to elevated GH and IGF-1. For most users, this resolves as the body acclimates. If retention is severe or persistent beyond 6 weeks, consider reducing the dose to 12.5mg daily or splitting the dose (12.5mg morning, 12.5mg evening). HGH injections can also cause water retention, but the effect tends to be more dose-dependent and controllable via titration. If water retention interferes with research protocol outcomes, HGH may offer more precise control.

Exogenous HGH delivers that predictability. Dose-response curves for recombinant somatotropin are linear and reproducible. 2 IU daily produces roughly 200–250 ng/mL IGF-1 in most adults. Peptide response varies based on pituitary reserve, sleep quality, and cortisol status. If you have documented GH deficiency (IGF-1 <100 ng/mL), HGH replacement is the appropriate intervention. If you have normal pituitary function and want optimization, peptides avoid the metabolic and legal risks.

Choose peptide-based protocols exclusively. Compounds like MK 677 and CJC-1295/Ipamorelin amplify endogenous GH secretion without shutting down pituitary function. You can cycle them indefinitely without creating hormone dependency. Exogenous HGH suppresses the hypothalamic-pituitary axis completely; stopping after 6+ months leaves you in a temporary deficiency state until natural pulsatility recovers.

Peptides are the safer choice. Chronic HGH exposure antagonizes insulin signaling, raising fasting glucose by 10–20 mg/dL and HbA1c by 0.3% over 12 months. Peptides produce minimal glucose impact (5–8 mg/dL) because GH pulses return to baseline between doses. If you're prediabetic or have a family history of type 2 diabetes, the metabolic load from sustained HGH therapy compounds your risk.